These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 15622778)
21. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen]. Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995 [TBL] [Abstract][Full Text] [Related]
22. [Therapeutic effects of chemotherapeutic regimens containing pirarubicin on the treatment of high-risk or refractory and relapsed acute leukemia in adults]. Li QH; DU X; Huang ZL; Luo CW; Zhong LY; Lin W Zhonghua Yi Xue Za Zhi; 2005 May; 85(17):1195-7. PubMed ID: 16029595 [TBL] [Abstract][Full Text] [Related]
23. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol. Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387 [TBL] [Abstract][Full Text] [Related]
24. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML). Jehn U; Heinemann V; Wilmanns W Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739 [TBL] [Abstract][Full Text] [Related]
25. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Cohen MH; Johnson JR; Justice R; Pazdur R Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926 [TBL] [Abstract][Full Text] [Related]
26. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors. Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754 [TBL] [Abstract][Full Text] [Related]
27. Phase II study of amsacrine gluconate in refractory leukemia. Omura GA; Winton EF; Vogler WR; Zuckerman KS; Grillo-Lopez AJ Cancer Treat Rep; 1983 Dec; 67(12):1131-2. PubMed ID: 6580948 [TBL] [Abstract][Full Text] [Related]
28. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia]. Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381 [TBL] [Abstract][Full Text] [Related]
29. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
30. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Specchia G; Pastore D; Carluccio P; Liso A; Mestice A; Rizzi R; Ciuffreda L; Pietrantuono G; Liso V Ann Hematol; 2005 Nov; 84(12):792-5. PubMed ID: 16047203 [TBL] [Abstract][Full Text] [Related]
31. AMSA--a promising new agent in refractory acute leukemia. Lawrence HJ; Ries CA; Reynolds RD; Lewis JP; Koretz MM; Torti FM Cancer Treat Rep; 1982 Jul; 66(7):1475-8. PubMed ID: 7046928 [TBL] [Abstract][Full Text] [Related]
32. New drugs in the treatment of acute and chronic leukaemia: current role of mAMSA. Jehn U Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():53-8. PubMed ID: 2697402 [TBL] [Abstract][Full Text] [Related]
33. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136 [TBL] [Abstract][Full Text] [Related]
34. Amsacrine in refractory adult acute leukemia: a pilot study of the Southeastern Cancer Study Group. Winton EF; Hearn EB; Vogler WR; Johnson L; Logan T; Raney M Cancer Treat Rep; 1983 Nov; 67(11):977-80. PubMed ID: 6580070 [TBL] [Abstract][Full Text] [Related]
35. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience. Yavuz S; Paydas S; Disel U; Sahin B Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532 [TBL] [Abstract][Full Text] [Related]
36. Treatment of recurrent promyelocytic leukemia with a combination regimen utilizing amsacrine, cytosine arabinoside and 6-thioguanine (AAT). Avvisati G; Petti MC; Petrucci MT; Falconi E; Tirindelli MC; Mandelli F Haematologica; 1989; 74(3):279-82. PubMed ID: 2511097 [TBL] [Abstract][Full Text] [Related]
37. Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. Arlin ZA; Feldman EJ; Mittelman A; Ahmed T; Puccio C; Chun HG; Cook P; Baskind P; Marboe C; Mehta R Cancer; 1991 Sep; 68(6):1198-200. PubMed ID: 1873770 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia. Petros WP; Rodman JH; Mirro J; Evans WE Cancer Chemother Pharmacol; 1991; 27(5):397-400. PubMed ID: 1999001 [TBL] [Abstract][Full Text] [Related]
39. Amsacrine treatment of patients with supraventricular arrhythmias and acute leukemia. Arlin Z; Mehta R; Feldman E; Sullivan P; Pucillo A Cancer Chemother Pharmacol; 1987; 19(2):163-4. PubMed ID: 3568274 [TBL] [Abstract][Full Text] [Related]
40. Factor X deficiency during treatment of relapsed acute myeloid leukaemia with amsacrine. Carter C; Winfield DA Clin Lab Haematol; 1988; 10(2):225-8. PubMed ID: 3166416 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]